Dr Luc-André Granier, M.D., PhD: President
Luc-André Granier founded Advicenne and has been Medical Director and Chairman of the Board since 2011. Luc-André Granier is an expert in the pharmaceutical development of innovative therapeutic products in the field of the central nervous system (CNS) with more than 25 years’ experience in the pharmaceutical (Eli Lilly and Co) and biotechnology (Synt:em, Forenap) industries. He has conducted a large number of clinical trials and led numerous programs for the development of drugs to treat neurological disorders, mainly in the fields of pain, migraine, neuro-degenerative diseases and psychiatric disorders. In particular, he successfully conducted the proof of concept study for the “blockbuster” duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004. Dr Granier obtained his degree as a Doctor of Medicine and Doctor of Science (in Biochemistry and Molecular and Cellular Biology) at the Louis Pasteur University in Strasbourg, France. He is a member of several national and international scientific societies, in particular in the fields of pain (SFETD, IHS, IASP) and epilepsy (ILAE).
Philippe Boucheron, MBA
Philippe Boucheron has an engineering degree in Biochemical Engineering and Microbial Genetics from the National Institute for Applied Sciences in Toulouse, an MSc in Biochemical Engineering from Polytechnique Montreal and an MBA from INSEAD (European Institute for Business Administration). From 1993 to 1996 Philippe Boucheron was a member of staff at BioCapital LP, one the largest Canadian risk capital funds devoted to biotechnology. From 1997 to 2000 he managed an average value shares research team at ING Barings Ferri in Paris, where he devoted a large part of his time to monitoring French and European biotechnology and health values. In 2000 he co-founded Bioam and became a member of the Board of Directors; in 2004 he was appointed Chairman of the Board. He has a seat on the councils of Aureus Pharma, Libragen, Ademtech, Integragen, Cryolog, SSI and TxCell. Following the merger of Bioam with CDC Entreprises in July 2010 Philippe Boucheron has joined the CDC Entreprises team for direct investment in life sciences (Innobio and Bioam funds).
Françoise Brunner-Ferber, PhD
Dr Françoise Brunner-Ferber, has more than 25 years’ experience in industry in Clinical Pharmacology, working for Merck Sharp and Dohme, Johnson and Johnson, and later for Marion Merrell Dow through its mergers with Hoechst Marion Roussel and Aventis. She spent 7 years as Head of the Zurich Subregion (MSD) and subsequently 10 years as Senior Director and Head of Clinical Pharmacology Europe.Her responsibilities included strong interfaces with preclinical development and research groups, aiming at a coordinated drug development strategy across the Atlantic. She has a keen interest in animal models, first-in-man studies, surrogate markers, and PK/PD relationship to support mechanisms of action and dose selection. She founded Brunner Naga, a consultant company, in 2001.
Renaud du Lac
Renaud du Lac, 59 years old, is President of IXO P.E., a leading independent investor in the South of France backing 13 companies in the healthcare/biotech sector. The in-depth knowledge of the local environment developed by Renaud du Lac over the past 25 years provides a helpful contribution to the ADVICENNE roadmap.
- Civil Engineer, Masters in Applied Economy from Paris IX Dauphine
- Experience in the oil industry
- Joined iXO PE (group) in 1989
- Appointed CEO of Institut Régional de Développement Industriel (IRDI) in 1999, President of iXO PE since 2003
- AFIC Administrator from 2002 to 2006, President of the Regional Action Commission
Jean-Pierre Lefoulon was born on 19 October 1932 and has degrees from the Ecole Polytechnique, the Ecole Nationale Supérieure des Télécommunications and the Institut Technique Bancaire du Conservatoire National des Arts and Métiers. Jean-Pierre Lefoulon started his career as a Consulting Engineer (BNCI) and then specialized in the financing of international complexes (e.g. Métro in Mexico). He then joined BNP as General Secretary of the International Division, then successively occupied the positions of BNP Network Director for North and South America, Director at the Regional General Directorate for the South-East of France, General Secretary of the BNP Business Bank (Banexi) and Director of the Financial Markets and Accounts Department at BNP. His functions have led him to participate with the Ministry of Finance and the Banque de France in the creation of new financial and monetary markets, and the creation of trading rooms in metropolitan France and abroad. As an administrator of MATIF and MONEP and several subsidiaries of BNP Investment Funds, he put in place the ALM (Asset and Liabilities Management) for the BNP balance sheet. Privately Mr Lefoulon was administrator for Laboratoire Delalande and CEO of its holding from 1966 to 1992. Currently he occupies the post of administrator for the CNIM and the Lille Municipal Council. He is Chairman of Value-Invest and the Lefoulon-Delalande Foundation.
Thibaut Roulon, Ph.D Investment Director, CDC Entreprises
A scientist by training Thibaut Roulon has been an investor in life sciences companies since 2005. Thibaut started his career as a scientist at Anosys Inc. (Menlo Park, CA, USA), a company developing cancer immunotherapeutics. In 2005 he joined Bioam Gestion, a venture capital firm investing in life sciences companies. In 2010, Bioam merged with CDC Enterprises, a leading French private equity firm. He is responsible for managing investments in life sciences companies (Bioam and InnoBio funds).
André Ulmann: M.D, Ph. D
André Ulmann’s professional career in the healthcare sector spans over 30 years in medical practice, research and the pharmaceutical industry. André’s knowledge of the development of pharmaceutical products and industry expertise is of great benefit as an advisor to Advicenne development. André founded HRA Pharma in 1996 and was the company’s Chief Executive Officer until he assumed the position of Chairman of the Board for the company in April 2009. Under his leadership, HRA Pharma has developed into a socially-committed pharmaceutical company that designs products, devices, and supporting services in niche areas of health, and makes them available to doctors and patients worldwide, reaching €33 million in sales in 2008. In 1999, HRA Pharma launched its first product, NorLevo. Known to the general public worldwide as “the morning-after pill”, NorLevo established HRA Pharma as a pioneer in emergency contraception. Now available in over 50 countries, NorLevo has enabled millions of women worldwide to have greater control over their own reproductive health than ever before. André’s career in healthcare began as a physician and he practiced at the Necker Hospital in Paris, where he was chief resident in Nephrology. André then joined the French company, Roussel-Uclaf, where he worked for over a decade. He began as International Project Leader for the development of RU 486. He was then appointed Medical Director of Laboratoire Roussel France and, following this, served at the helm of four different therapeutic areas within Roussel-Uclaf and Hoechst-Marion-Roussel: international clinical research, endocrinology and immunology, neurobiology, and bone diseases.